Application of macrophage inhibiting factor-1 in colorectal cancer diagnosis

Abstract

The invention relates to an application of a macrophage inhibiting factor-1 in colorectal cancer diagnosis, and in particular relates to an application of a tumor marker in preparation of a reagent or a kit for diagnosing and / or monitoring colorectal cancer of a subject, wherein the tumor marker comprises the macrophage inhibiting factor-1 and a TPS. The invention further relates to the reagent or the kit for diagnosing and / or monitoring colorectal cancer of the subject, and the reagent or the kit comprises a reagent for detecting the tumor marker. The tumor market provided by the invention has good complementarity, can greatly improve the detection efficiency of colorectal cancer, and has a good application prospect.

Description

technical field [0001] The invention relates to the field of diagnosis and monitoring of colorectal cancer. Specifically, the present invention relates to the application of macrophage inhibitory factor 1 in the diagnosis and monitoring of colorectal cancer, especially relates to the application of macrophage inhibitory factor 1 in combination with other tumor markers such as MIC-1, CEA, TPS in colorectal cancer, especially in the early stage Applications in the diagnosis of colorectal cancer. Background technique [0002] Colorectal cancer includes colon cancer and rectal cancer, and its death rate ranks fourth in urban areas and fifth in rural areas. Most of the patients with early colorectal cancer have no obvious clinical symptoms and signs. Once discovered, they will be in the middle and late stages. In my country, the incidence of colorectal cancer has a clear upward trend, and it is a major threat to human health. Early detection of colorectal cancer can effectively...

AI Technical Summary

Problems solved by technology

CEA is the earliest serum tumor marker for colorectal cancer discovered. It is a glycoprotein with a molecular weight of about 180kD. The coding gene is located on chromosome 19. CEA is elevated to varying degrees in most malignant tumor serum, and is often used clinically as a digestive tract marker. An auxiliary diagnostic index for malignant tumors, but the sensitivity and specificity of its detection cannot meet the needs of clinical detection, and the positive rate of preoperative CEA is about 30%-40%

The CA series is mainly expressed on the cancerous cell membrane and can be released into the interstitium, so it can be used for tumor diagnosis and treatment monitoring. Currently, CA199, CA125, CA242 and CA724 are commonly used in the diagnosis of colorectal cancer. Studies have found that CA series antigens There is a correlation with tumor size, Bormann classification, lymphatic invasion and pathological type, which is of great value in the diagnosis and treatment of colorectal cancer, but there are also problems of poor sensitivity and specificity. The diagnosis of a single CA marker Less than 30% sensitivity

[0005] A large number of studies have shown that even if the CEA, TPA and CA series are combined, the sensitivity of diagnosing colorectal cancer is still less than 60%, and the clinical significance is limited. What is especially insufficient is that the sensitivity of the three combined to diagnose early (stage I+II) colorectal cancer is less than 30%.

Images